SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, tibt913
Search This Board: 
Last Post: 3/27/2017 7:27:17 PM - Followers: 189 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#12217  Sticky Note Canncodex tibt913 03/24/17 07:32:48 PM
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#12270   All ask slaps today. RCHA ready here. OTC Knight 03/27/17 07:27:17 PM
#12269   Good luck with all the diluting yet to Axeman 03/27/17 02:43:38 PM
#12268   New wow Rich Pharmaceuticals to Launch CannCodex, marking its Shortheidman 03/27/17 02:13:24 PM
#12267   New wow Press Release: Rich Pharmaceuticals Attracts New Financing Shortheidman 03/27/17 02:12:57 PM
#12266   New wow Rich Pharmaceuticals Attracts New Financing Package with Shortheidman 03/27/17 02:12:30 PM
#12265   Yep - it was stellar news. More good OTC Knight 03/27/17 01:29:49 PM
#12264   Recent News - Rich Pharmaceuticals to Launch CannCodex, PENNYMACHINE 03/27/17 01:15:11 PM
#12263   Exactly. 0003 close very possible today IMO. OTC Knight 03/27/17 01:06:59 PM
#12262   0002s will go soon enough. A slap here jmorexxnet 03/27/17 12:33:43 PM
#12261   A bunch of nice milly slaps on 2s OTC Knight 03/27/17 12:23:18 PM
#12260   500 Million supports! Huge! MojoTrader 03/27/17 12:16:05 PM
#12259   2s clearing out here!!! OTC Knight 03/27/17 11:50:38 AM
#12258   Now only 2 donkeys left on ask!!! OTC Knight 03/27/17 11:50:01 AM
#12257   Nice consolidation going on! MojoTrader 03/27/17 11:45:23 AM
#12256   RCHA impressive buying here gh0st 03/27/17 11:43:20 AM
#12255   Exactly!!! OTC Knight 03/27/17 11:40:05 AM
#12254   Nice Blocks hitting, This one ready to bounce? PENNYMACHINE 03/27/17 11:37:56 AM
#12253   nice slap at 2 we going steez 03/27/17 11:35:37 AM
#12252   Just look at the massive buys on 2s. OTC Knight 03/27/17 11:23:01 AM
#12251   Level 2 shows 0003s got tapped today!!! OTC Knight 03/27/17 11:10:12 AM
#12250   ASK getting thinner. Only 3 donkeys left!!! OTC Knight 03/27/17 11:09:58 AM
#12249   LETS GO RCHA!! Atrain1725 03/27/17 11:09:13 AM
#12248   Congrats. Now let others enjoy their trade. Thanks! jmorexxnet 03/27/17 09:16:45 AM
#12247   MILLIONS OF DUMPS .0001 Global Supermodel 03/27/17 08:39:55 AM
#12246   They need massive non fluff news so they Axeman 03/26/17 03:18:20 PM
#12244   And now you are bidsitting and if you OTC Knight 03/26/17 01:35:49 PM
#12243   Good grab there. Easy double soon. More news OTC Knight 03/26/17 01:34:14 PM
#12242   Exactly, that was before i witnessed the massive, Global Supermodel 03/26/17 01:33:45 PM
#12241   Agreed 100%. 2s are getting slapped hard. OTC Knight 03/26/17 01:33:06 PM
#12240   I'll write you back on Friday laughing when Global Supermodel 03/26/17 01:32:22 PM
#12239   Massive buys at .0002s OTC Knight 03/26/17 01:32:01 PM
#12238   Only 8 followers? And you are giving investment OTC Knight 03/26/17 01:30:39 PM
#12237   Go tell that to a rookie. Look at Global Supermodel 03/26/17 01:28:26 PM
#12236   Wrong - those shares went into stronger hands. OTC Knight 03/26/17 01:25:59 PM
#12235   Yea, i saw them, but i also saw Global Supermodel 03/26/17 01:25:11 PM
#12234   I know few of us invested a least MojoTrader 03/26/17 01:22:20 PM
#12233   Didn't you see all the milly slaps on OTC Knight 03/26/17 01:21:35 PM
#12232   Agreed. Volume/accumulation is huge here. OTC Knight 03/26/17 01:20:34 PM
#12231   Yes! The next TXTM! MojoTrader 03/26/17 01:19:12 PM
#12230   I'm ready to see 0003s again here. OTC Knight 03/26/17 01:18:05 PM
#12229   Toxic dump and going to continue. Axeman 03/26/17 11:26:21 AM
#12228   Yea, from a bunch on people then trying Global Supermodel 03/26/17 10:36:54 AM
#12227   Dump or not that 172 million share costs tibt913 03/26/17 10:19:07 AM
#12225   tibt913 03/26/17 10:05:25 AM
#12224   172 million dump @.0001 Global Supermodel 03/26/17 07:40:10 AM
#12222   Agreed, plenty of upside here. jmorexxnet 03/25/17 06:27:27 PM
#12221   This is why I'm IN! The next MojoTrader 03/25/17 08:27:03 AM
#12219   Where's the huge potential? Didn't you Global Supermodel 03/24/17 09:38:14 PM
#12218   News this week was huge. Huge potential here. OTC Knight 03/24/17 07:34:21 PM
#12217   Canncodex tibt913 03/24/17 07:32:48 PM